[1]
|
D. M. Parkin, F. Bray, J. Ferlay and P. Pisani, “Global Cancer Statistics, 2002,” CA: A Cancer Journal for Clinicians, Vol. 55, No. 2, 2005, pp. 74-108.
doi:10.3322/canjclin.55.2.74
|
[2]
|
A. de Gramont, A. Figer, M. Seymour, et al., “Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer,” Journal of Clinical Oncology, Vol. 18, No. 16, 2000, pp. 2938-2947.
|
[3]
|
J. Y. Douillard, D. Cunningham, A. D. Roth, et al., “Irinotecan Combined with Fluorouracil Compared with Fluorouracil Alone as First-Line Treatment for Metastatic Colorectal Cancer: A Multicentre Randomised Trial,” Lancet, Vol. 355, No. 9209, 2000, pp. 1041-1047.
doi:10.1016/S0140-6736(00)02034-1
|
[4]
|
H. Kock, M. Pietsch, U. Krause, H. Wilke and F. Eigler, “Implantable Vascular Access Systems: Experience in 1500 Patients with Totally Implanted Central Venous Port Systems,” World Journal of Surgery, Vol. 22, No. 1, 1998, pp. 12-16. doi:10.1007/s002689900342
|
[5]
|
J. M. Davies and R. M. Goldberg, “Treatment of Metastatic Colorectal Cancer,” Seminars in Oncology, Vol. 38, No. 4, 2011, pp. 552-560.
doi:10.1053/j.seminoncol.2011.05.009
|
[6]
|
K. M. Tveit, T. Guren, B. Glimelius, et al., “Phase IIII Trial of Cetuximab with Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic Flox) versus Flox Alone in First-Line Treatment of Metastatic Colorectal Cancer: The Nordic-Vii Study,” Journal of Clinical Oncology, Vol. 30, No. 15, 2012, pp. 1755-1762.
doi:10.1200/JCO.2011.38.0915
|
[7]
|
T. S. Maughan, R. A. Adams, C. G. Smith, et al., “Addition of Cetuximab to Oxaliplatin-Based First-Line Combination Chemotherapy for Treatment of Advanced Colorectal Cancer: Results of the Randomised Phase 3 Mrc Coin Trial,” Lancet, Vol. 377, No. 9783, 2011, pp. 2103-2114. doi:10.1016/S0140-6736(11)60613-2
|
[8]
|
J. Y. Douillard, S. Siena, J. Cassidy, et al., “Randomized, Phase III Trial of Panitumumab with Infusional Fluorouracil, Leucovorin, and Oxaliplatin (Folfox4) versus Folfox4 Alone as First-Line Treatment in Patients with Previously Untreated Metastatic Colorectal Cancer: The Prime Study,” Journal of Clinical Oncology, Vol. 28, No. 31, 2010, pp. 4697-4705.
doi:10.1200/JCO.2009.27.4860
|
[9]
|
E. Van Cutsem, C. H. Kohne, E. Hitre, et al., “Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer,” The New England Journal of Medicine, Vol. 360, No. 14, 2009, pp. 1408-1417.
doi:10.1056/NEJMoa0805019
|
[10]
|
L. Schulmeister, “Management of Non-Infectious Central Venous Access Device Complications,” Seminars in Oncology Nursing, Vol. 26, No. 2, 2010, pp. 132-141.
doi:10.1016/j.soncn.2010.02.003
|
[11]
|
M. Lorenz, C. Hottenrott, R. M. Seufert and A. Encke, “A Totally Implantable Permanent Central Venous Access, Long-Term Experience with Subcutaneous Infusion Chambers (German),” Langenbeck’s Archives of Surgery, Vol. 373, No. 5, 1988, pp. 302-309. doi:10.1007/BF01276546
|
[12]
|
R. Poorter, F. Lauw, W. Bemelman, et al., “Complications of an Implantable Venous Access Device (Port-a-Cath) During Intermittent Continuous Infusion of Chemotherapy,” European Journal of Cancer, Vol. 13, No. 1996, pp. 2262-2266.
|
[13]
|
B. Yung, I. A. Cambell, J. S. Elborn, J. S. Harvey and D. J. Shale, “Totally Implantable Venous Access Devices in Adult Patients with Cystic Fibrosis,” Respiratory Medicine, Vol. 90, No. 1996, pp. 353-356.
|
[14]
|
R. Schwarz, J. Groeger and D. Coit, “Subcutaneously Implanted Central Venous Access Devices in Cancer Patients: A Prospective Analysis,” Cancer, Vol. 79, No. 8, 1997, pp. 1635-1640.
doi:10.1002/(SICI)1097-0142(19970415)79:8<1635::AID-CNCR30>3.0.CO;2-X
|
[15]
|
L. Laurenzi, C. Fimiani, S. Natoli, et al., “Complications with Fully Umplantable Venous Access Systems in Oncologic Patients,” Tumori, Vol. 82, No. 1996, pp. 232-236.
|
[16]
|
M. Hollyoak, T. Ong and J. Leditschke, “Critical Appraisal of Surgical Venous Access in Children,” Pediatric Surgery International, Vol. 12, No. 2-3, 1997, pp. 177-182. doi:10.1007/BF01349993
|
[17]
|
P. Craft, J. May, A. Dorigo, C. Hoy and A. Plant, “Hickman Catheters: Left-Sided Insertion, Male Gender, and Obesity Are Associated with an Increased Risk of Complications,” Australian and New Zealand Journal of Medicine, Vol. 26, No. 1, 1996, pp. 33-39.
doi:10.1111/j.1445-5994.1996.tb02904.x
|
[18]
|
P. Carde, M. Cosset-Delaigue, A. Laplanche and I. Chareau, “Classical External Indwelling Central Venous Catheter versus Totally Implanted Venous Access Systems for Chemotherapy Administration: A Randomized Trial in 100 Patients with Solid Tumors,” European Journal of Cancer and Clinical Oncology, Vol. 25, No. 6, 1989, pp. 939-944. doi:10.1016/0277-5379(89)90151-X
|
[19]
|
P. Osterlund, T. Ruotsalainen, R. Korpela, et al., “Lactobacillus Supplementation for Diarrhoea Related to Chemotherapy of Colorectal Cancer: A Randomised Study,” British Journal of Cancer, Vol. 97, No. 8, 2007, pp. 1028-1034. doi:10.1038/sj.bjc.6603990
|
[20]
|
G. Nazarian, H. Bjarnason, C. Dietz, Jr., C. Bernadas and D. Hunter, “Changes in Tunneled Catheter Tip Position When a Patient Is Upright,” Journal of Vascular and Interventional Radiology, Vol. 8, No. 3, 1997, pp. 437-441. doi:10.1016/S1051-0443(97)70585-2
|
[21]
|
L. Bishop, L. Dougherty, A. Bodenham, et al., “Guidelines on the Insertion and Management of Central Venous Access Devices in Adults,” International Journal of Laboratory Hematology, Vol. 29, No. 4, 2007, pp. 261-278.
doi:10.1111/j.1751-553X.2007.00931.x
|
[22]
|
J. Petersen, J. Delaney, M. Brakstad, R. Rowbotham and C. Bagley, Jr., “Silicone Venous Access Devices Positioned with Their Tips High in the Superior Vena Cava Are More Likely to Malfunction,” The American Journal of Surgery, Vol. 178, No. 1, 1999, pp. 38-41.
doi:10.1016/S0002-9610(99)00124-5
|
[23]
|
T. M. Vesely, “Central Venous Catheter Tip Position: A Continuing Controversy,” Journal of Vascular and Interventional Radiology, Vol. 14, No. 5, 2003, pp. 527-534.
doi:10.1097/01.RVI.0000071097.76348.72
|
[24]
|
G. Stanislav, R. Fitzgibbons, Jr., R. Bailey, Jr., et al., “Reliability of Implantable Central Venous Access De- vices in Patients with Cancer,” Archives of Surgery, Vol. 122, No. 11, 1987, pp. 1280-1283.
doi:10.1001/archsurg.1987.01400230066012
|
[25]
|
C. Kowalski, J. Kaufman, S. Rivitz, S. Geller and A. Waltman, “Migration of Central Venous Catheters: Implications for Initial Catheter Tip Positioning,” Journal of Vascular and Interventional Radiology, Vol. 8, No. 3, 1997, pp. 443-447.
|
[26]
|
R. DeChicco, D. L. Seidner, C. Brun, et al., “Tip Position of Long-Term Central Venous Access Devices Used for Parenteral Nutrition,” Journal of Parenteral and Enteral Nutrition, Vol. 31, No. 5, 2007, pp. 382-387.
doi:10.1177/0148607107031005382
|
[27]
|
P. Rasuli, D. Hammond and I. Peterkin, “Spontaneous Intrajugular Migration of Long-Term Central Venous Access Catheters,” Radiology, Vol. 182, No. 3, 1992, pp. 822-824.
|
[28]
|
M. Binnebosel, J. Grommes, K. Junge, et al., “Internal Jugular Vein Thrombosis Presenting as a Painful Neck Mass Due to a Spontaneous Dislocated Subclavian Port Catheter as Long-Term Complication: A Case Report,” Cases Journal, Vol. 2, No. 7991, 2009, p. 7991.
doi:10.4076/1757-1626-2-7991
|